Exacerbation of myasthenia gravis by intravenous peramivir

Muscle and Nerve

Volumn 51, Issue 6, 2015, Pages 935-936

  Hayashi, Koji ^a   Iwasa, Kazuo ^a   Morinaga, Akiyoshi ^a   Ono, Kenjiro ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; PERAMIVIR; PREDNISOLONE; TACROLIMUS; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; AGED; BREATHING; CASE REPORT; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLUENZA A; LETTER; MEDICAL HISTORY; MYASTHENIA GRAVIS; NERVE STIMULATION; PRIORITY JOURNAL; REPETITIVE NERVE STIMULATION; THYMECTOMY; THYMOMA; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; AGED; CYCLOPENTANES; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; MYASTHENIA GRAVIS;

EID: 84929505936     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24594     Document Type: Letter

References (8)

1. O'Riordan JI, Miller DH, Mottershead JP, Hirsch NP, Howard RS. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 1998;5:137-142.
2. Pascuzzi RM. Prepared by the Professional and Public Information Committee Myasthenia Gravis Foundation of America: Medications and myasthenia gravis (a reference for Health Care Professionals). Available at http://www.myasthenia.org/LinkClick.aspx?fileticket=JuFvZPPq2vg%3d. Accessed September 26, 2014.
3. Harnett MT, Chen W, Smith SM. Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness. Neuropharmacology 2009;57:502-505.
4. Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 2011;34:839-847.
5. Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010;628:6-10.
6. Muraki K, Hatano N, Suzuki H, Muraki Y, Iwajima Y, Maeda Y, et al. Oseltamivir blocks human neuronal nicotinic acetylcholine receptor-mediated currents. Basic Clin Pharmacol Toxicol 2015;116:87-95.
7. Kimura S, Niwa Y, Iwajima Y, Nagano Y, Yamamoto S, Ohi Y, et al. High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats. Basic Clin Pharmacol Toxicol 2012;111:232-239.
8. Marty FM, Man CY, van der Horst C, Francois B, Garot D, Manez R, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis 2014;209:542-550.